成人生长激素缺乏症生长激素替代治疗的肿瘤发生风险Meta分析

发布时间：2018-04-17 02:20

  本文选题：成人生长激素缺乏症 + 生长激素替代治疗　； 参考：《浙江大学》2015年硕士论文

【摘要】：目的：成人生长激素缺乏症可致机体组分改变、糖脂代谢紊乱、骨代谢异常、心血管疾病风险增加等,生长激素替代治疗可有效改善以上情况,但生长激素替代治疗的安全性目前仍备受争议,尤其在肿瘤发生风险方面。目前已知国内外发表的文章中尚未有关于这方面的统计,本文通过对国内外有关生长激素替代治疗对成人生长激素缺乏症患者肿瘤发生风险相关研究进行定量统计分析,旨在探讨生长激素替代治疗是否增加成人生长激素缺乏症患者肿瘤发生风险。 方法：应用Cochrane系统评价方法,对PUBMED、Web of Science、Ovid、Cochrane、中国生物医学文献数据库(CBM)、相关期刊论文(CNKI)、万方数据库自建库以来至2015年3月所有文献进行检索。文献语种为中文和英文。查找符合纳入标准的随机对照试验和队列研究,对其进行质量评价,使用Revman5.0软件对提取的相关数据进行meta分析。 结果：本文共纳入8个队列研究,总共11106名AGHD患者,平均随访时间为7.4年。结果显示GH治疗组的AGHD患者肿瘤发生的风险较非GH治疗组无增加。亚组分析显示回顾性及前瞻性队列研究中GH治疗组与非GH治疗组相比较肿瘤发生风险无增加。样本量≤000例和样本量1000例的研究中GH治疗组与非GH治疗组相比较肿瘤发生风险无增加。 结论：本meta分析结果显示,AGHD患者使用GH替代治疗与未使用GH替代治疗相比,肿瘤发生风险未增加。
[Abstract]:Objective: adult growth hormone deficiency can cause changes in body composition, disorder of glucose and lipid metabolism, abnormal bone metabolism, increased risk of cardiovascular disease, etc. Growth hormone replacement therapy can effectively improve these conditions.However, the safety of growth hormone replacement therapy is still controversial, especially in cancer risk.At present, there are no statistics on this aspect in the articles published at home and abroad. This paper makes a quantitative statistical analysis on the risk of tumor occurrence in adult growth hormone deficiency patients by using the growth hormone replacement therapy at home and abroad.Objective to investigate whether growth hormone replacement therapy increases the risk of tumor in adults with growth hormone deficiency.Methods: using the method of Cochrane system evaluation, all the literatures of PUBMEDU Web of Science Ovidor Cochrane, China Biomedical Literature Database, China Journal Full-text Database and Wanfang Database were searched from time to March 2015.The languages of the literature are Chinese and English.Random controlled trials and cohort studies that meet the inclusion criteria were searched for quality evaluation and meta analysis of the extracted data was carried out using Revman5.0 software.Results: a total of 11106 AGHD patients were enrolled in 8 cohort studies with an average follow-up time of 7.4 years.The results showed that there was no increase in tumor risk in GH group compared with non-GH group.Subgroup analysis showed that there was no increase in tumor risk in the GH group compared with the non-GH group in a retrospective and prospective cohort study.In the study of sample size 鈮，

本文编号：1761641